Testing Fmr1(KO) Phenotypes in Response to GSK3 Inhibitors: SB216763 versus AFC03127

Glycogen synthase kinase 3 (GSK3) is a proline-directed serine-threonine kinase that is associated with several neurological disorders, including Alzheimer’s disease and fragile X syndrome (FXS). We tested the efficacy of a novel GSK3 inhibitor AFC03127, which was developed by Angelini Pharma, in co...

Descripción completa

Detalles Bibliográficos
Autores principales: Westmark, Pamela R., Garrone, Beatrice, Ombrato, Rosella, Milanese, Claudio, Di Giorgio, Francesco Paolo, Westmark, Cara J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Molecular Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529056/
https://www.ncbi.nlm.nih.gov/pubmed/34690696
http://dx.doi.org/10.3389/fnmol.2021.751307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529056/
https://www.ncbi.nlm.nih.gov/pubmed/34690696
http://dx.doi.org/10.3389/fnmol.2021.751307

Ejemplares similares